News
MinervaX reveals financing to development group B streptococcus vaccine
MinervaX – a company developing a novel vaccine against group B streptococcus (GBS) – has announced the successful completion of a €72m financing round.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
MinervaX – a company developing a novel vaccine against group B streptococcus (GBS) – has announced the successful completion of a €72m financing round.